Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yinxiang Cheng"'
Autor:
Yihua Jiang, Yinxiang Cheng, Mengyuan Xia, Bingrui Zhang, Qiaoce Ding, Liye Lu, Jian-Rong Wang, Xuefeng Mei
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2478 (2022)
Dehydroepiandrosterone (DHEA) is an FDA-approved food supplement used as an assisted reproductive sex hormone. The bioavailability is severely limited by its poor solubility (23 µg/mL). Herein, we aimed to modulate its solubility through cocrystalli
Externí odkaz:
https://doaj.org/article/ce6f126bf7ee4d30bd7c41bcae7ffa1c
Autor:
Fu Xiao, Yinxiang Cheng, Jian-Rong Wang, Dingyan Wang, Yuanyuan Zhang, Kaixian Chen, Xuefeng Mei, Xiaomin Luo
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2198 (2022)
Bexarotene (BEX) was approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL). The poor aqueous solubility causes the low bioavailability of the drug and thereby limits the clinical application. In this study, we developed a
Externí odkaz:
https://doaj.org/article/bb48dbfe1cc540c598a832fb87eba110
Publikováno v:
Crystal Growth & Design. 22:7285-7297
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::689fab57b1cb37311e6f2e1c9086902c
https://doi.org/10.1021/acs.cgd.2c00919
https://doi.org/10.1021/acs.cgd.2c00919
Autor:
Yinxiang Cheng, Yihua Jiang, Bingrui Zhang, Xiaoyi Rong, Qiaoce Ding, Zaiyong Zhang, Jian-Rong Wang, Xuefeng Mei
Publikováno v:
Crystal Growth & Design. 22:7469-7477
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b407828e6b8ed1c39cdda7c1e9c193a5
https://doi.org/10.1021/acs.cgd.2c01043
https://doi.org/10.1021/acs.cgd.2c01043
Autor:
Mengyuan, Xia, Yihua, Jiang, Yinxiang, Cheng, Wenjuan, Dai, Xiaoyi, Rong, Bingqing, Zhu, Xuefeng, Mei
Publikováno v:
International Journal of Pharmaceutics. 631:122461
Rucaparib (Ruc) is a drug used to treat advanced ovarian cancer associated with deleterious BRCA mutations. Its commercial form, the camsylate salt (Ruc-Cam), suffers from poor aqueous solubility and thus causes low and erratic oral bioavailability.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a84586228eeafb63209f1e53210b1856
https://doi.org/10.1016/j.ijpharm.2022.122461
https://doi.org/10.1016/j.ijpharm.2022.122461
Publikováno v:
International journal of pharmaceutics. 610
Isotretinoin is the first-line drug for treatment of severe acne. Only one polymorph was reported even though it has been launched for nearly 40 years, and its clinic application was however limited by its stability and solubility challenges. In our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecfce3c17b7e19900209b23add88a91c
https://pubmed.ncbi.nlm.nih.gov/34699948
https://pubmed.ncbi.nlm.nih.gov/34699948